Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) CEO Neil Clark speaks to Proactive after releasing fresh data from the update from a research collaboration into a novel biotherapeutic treatment for COVID-19 and influenza.
Clark says that the project has already delivered "more than hoped for" and that it will be "really interesting to see where [it] goes next."